Gerresheimer (ETR:GXI) PT Set at €80.00 by Deutsche Bank

Gerresheimer (ETR:GXI) has been given a €80.00 ($93.02) target price by equities research analysts at Deutsche Bank in a note issued to investors on Wednesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price target would indicate a potential upside of 20.03% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Berenberg Bank set a €81.00 ($94.19) target price on shares of Gerresheimer and gave the company a “buy” rating in a report on Thursday, October 10th. DZ Bank restated a “neutral” rating on shares of Gerresheimer in a report on Friday, October 11th. Credit Suisse Group set a €87.00 ($101.16) target price on shares of Gerresheimer and gave the company a “buy” rating in a report on Tuesday, October 15th. Goldman Sachs Group set a €65.00 ($75.58) target price on shares of Gerresheimer and gave the company a “neutral” rating in a report on Tuesday. Finally, HSBC set a €85.00 ($98.84) target price on shares of Gerresheimer and gave the company a “buy” rating in a report on Monday, October 14th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of €71.11 ($82.69).

Shares of ETR:GXI traded down €0.35 ($0.41) during mid-day trading on Wednesday, reaching €66.65 ($77.50). 191,613 shares of the company’s stock were exchanged, compared to its average volume of 140,925. The firm has a market capitalization of $2.06 billion and a price-to-earnings ratio of 10.11. The business’s fifty day moving average price is €68.99 and its 200-day moving average price is €67.92. The company has a debt-to-equity ratio of 65.99, a quick ratio of 0.54 and a current ratio of 0.81. Gerresheimer has a twelve month low of €51.10 ($59.42) and a twelve month high of €74.80 ($86.98).

Gerresheimer Company Profile

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Recommended Story: The risks of owning bonds

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.